Heparanase-specific shRNA: A novel therapeutic strategy in human gastric cancer

Nov 25, 2009

Previous studies have indicated that the heparanase (HPA) is correlated with histopathological parameters and poor prognosis of gastric cancers. Although their efficiencies in inhibiting the expression of HPA, the traditional HPA inhibitors may produce nonspecific and undesirable effects. In recent years, genetic approaches targeting HPA have been regarded as a promising alternative.

Antisense oligonucleotides, ribozyme, and small (siRNA) have been developed to decrease the HPA expression. However, it remains unknown whether stable transfection of short hairpin RNA (shRNA) can knockdown the HPA expression and decrease the invasiveness and metastasis of cells.

A research team from China reported such research examining the effects of HPA-specific shRNA on the cultured gastric . Results showed that stable transfection of HPA-specific shRNA, but not of scrambled shRNA and mock vector, resulted in reduced mRNA and protein levels of HPA. The shRNA-mediated knockdown of HPA did not affect the of SGC-7901 cells. However, the in vitro invasiveness and metastasis of cancer cells were decreased after knockdown of HPA. Moreover, transfection of HPA-specific shRNA decreased the in vitro angiogenesis capabilities of SGC-7901 cells. Their study was published on November 21, 2009 in the .

Their research suggested that HPA-specific shRNA may be of potential value as a novel therapeutic strategy in human gastric cancer and may be also applicable for the therapies of other cancers overexpressing HPA.

More information: Zheng LD, Jiang GS, Pu JR, Mei H, Dong JH, Hou XH, Tong QS. Stable knockdown of heparanase expression in gastric cancer cells in vitro. World J Gastroenterol 2009; 15(43): 5442-5448, www.wjgnet.com/1007-9327/15/5442.asp

Source: World Journal of Gastroenterology (news : web)

Explore further: Unplanned hospitalizations with GI cancer patients common

add to favorites email to friend print save as pdf

Related Stories

Yes-associated protein: Early diagnosis of gastric carcinoma

Sep 17, 2009

Yes-associated protein (YAP) is a type of cellular adaptor protein and transcriptional co-activator. In recent years, some investigators have found YAP to be overexpressed and highly activated in hepatic cancers and mammary ...

Experimental agent reduces breast cancer metastasis to bone

Nov 03, 2009

Researchers have reduced breast cancer metastasis to bone using an experimental agent to inhibit ROCK, a protein that was found to be over-expressed in metastatic breast cancer. In a study in mice, the team of researchers ...

Recommended for you

Blood biomarker may detect lung cancer

11 hours ago

A new study shows that patients with stage I to stage III non-small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract ...

ACG: Recent increase in incidence of young-onset CRC

Oct 20, 2014

(HealthDay)—The incidence of young-onset colorectal cancer (CRC) is increasing, and the disease is more aggressive pathologically. These findings are being presented at the annual meeting of the American ...

User comments : 0